ArticleMolecular therapy oncolytics2021
Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma.
Hui Yu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
32 papers cite it
this papertrialcites it